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The Concept {#sec2_1}
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Metastatic spread of the primary is still defined as the systemic stage of disease in treatment guidelines for various solid tumors. This definition is the rationale for systemic therapy whose effectiveness has evolved tremendously over the past decades due to the introduction of new substances and schemes and the implementation of antibody-including regimens \[[@B1],[@B2]\]. However, the systemic effect(ivity) goes along with a systemic toxicity profile, which, on the one hand, hampers its applicability in comorbid patients. On the other hand, systemic treatments are often related to diminished quality of life \[[@B3],[@B4],[@B5]\]. Interestingly and despite the concept of systemic involvement, surgical resection as a local treatment has proven long-term outcomes in a subset of patients with limited metastatic disease \[[@B6],[@B7],[@B8],[@B9]\]. In expansion of these data, the concept of oligometastatic disease has evolved, defined as a tumor pattern with limited metastatic spread in biologically favorable tumors in regard to growth dynamics, future systemic spread, and thus overall prognosis \[[@B10],[@B11],[@B12]\]. Furthermore, this concept of limited metastatic disease claims for local treatments beyond resection, keeping in mind that only a minority of patients are eligible for the surgical approach \[[@B13]\]. Beyond surgical resection, a long-term observational study of metastatic colorectal disease indicated impressive overall survival (OS) in unresectable patients treated with radiofrequency ablation (RFA) as compared to the published outcomes after surgery \[[@B14]\]. Some studies comparing patient cohorts undergoing RFA to surgery directly but non-randomized yielded inferior outcomes for the image-guided radiofrequency approach. However, most of these studies display a strong selection bias, and prospective randomized data comparing surgery and the image-guided approach is not available today \[[@B15],[@B16],[@B17],[@B18]\]. In colorectal liver metastasis, the CLOCC trial revealed a significantly higher progression-free survival (PFS) in patients receiving RFA plus systemic chemotherapy versus systemic therapy alone in first-line treatment of metastatic colorectal cancer \[[@B19]\]. The study was not powered for survival. However, median survival was 45 months versus 40 months in favor of the combined treatment.

Some studies demonstrate similar local control rates following RFA or surgery in selected tumor entities (such as neuroendocrine carcinoma) \[[@B20],[@B21]\]. In early and very early hepatocellular carcinoma (HCC), RFA is a suboptimal standard method \[[@B22]\]. Emerging evidence suggests that in small HCCs in cirrhotic patients image-guided percutaneous RFA even yields favorable OS similar or even favorable to resection \[[@B23],\]\[[@B24]\]. In addition to such efforts reaching out to potentially curative treatment intentions, aggressive cytoreduction in advanced stages of metastatic gastrointestinal tumors applying locoregional treatments such as Yttrium-90 (Y90) radioembolization (RE) in combination with systemic treatments are under research (SIRFLOX, NCT00724503, SIR-STEP, NCT01895257). Recent advances in invasive and non-invasive radiotherapeutic techniques, imaging, and integrated planning algorithms have opened a gate with remarkably expanded options towards which patients are technically applicable. The specific value of these methods as well as the proper indication still is under scrutiny.

Local Non-Surgical Approaches: The Options {#sec2_2}
------------------------------------------

In general, one may discriminate between thermal-physical (e.g. RFA, laser-induced thermal therapy (LITT)), chemical (transarterial embolisation (TAE), or transarterial chemoembolisation (TACE)) and radiooncological procedures (e.g. stereotactic body radiation therapy (SBRT), high-dose-rate (HDR) interstitial brachytherapy (iBT), and Y90-RE)) \[[@B25],[@B26],[@B27],[@B28],[@B29],[@B30],[@B31],[@B32],[@B33],[@B34],[@B35]\]. RFA is currently the most frequently applied technique, foremost in non-resectable tumors of the liver and lung \[[@B36],[@B37],[@B38],[@B39]\]. Therefore, RFA is well described, but -- as a thermal ablative method -- it inheres some technical restrictions due to the tumor size and location \[[@B40],[@B41]\]. Radiotherapeutic techniques may overcome these limitations.

Radiation to liver tumors may be applied percutaneously by SBRT or cyberknife techniques \[[@B42]\]. HDR-iBT is a technique employing a point source, e.g. iridium-192 (^192^Ir), delivered through catheters which have been implanted in the tumor under computed therapy (CT) guidance. The technique allows the delivery of excessive doses inside the target volume while saving adjacent structures from potentially harmful exposure due to favorable decay characteristics distant to the point source. It overcomes size limits and restrictions induced by tumor location, e.g. close proximity to the liver hilum or large vessels. It also overcomes constraints of percutaneous, non-invasive irradiation techniques by avoiding overexposure of the surrounding tissue while providing the opportunity to apply high doses to the tumor \[[@B29],[@B43],[@B44],[@B45]\].

Furthermore, in more advanced stages with hepatic dominant disease, Y90-RE (selective internal radiation therapy (SIRT)) is an alternative option to deliver a rather locoregional treatment in liver malignancies. This treatment is based on intra-arterial application of Y90 isotopes coupled to microspheres of distinct sizes, enabling their delivery into atypical tumor vessels rather than to arteries feeding regular liver parenchyma \[[@B46]\]. However, since the distribution of the particles always induces exposure of normal liver parenchyma as well, only patients with a preserved liver function are qualified, and distinctive preliminaries and tests to avoid undesired extrahepatic deposits of microspheres and deterioration of liver function are necessary.

Radioablative Local Techniques {#sec1_2}
==============================

Stereotactic Radiotherapy (SRT) for Brain Tumors {#sec2_3}
------------------------------------------------

Especially during the last two decades, radiooncology has undergone tremendous advances by highly sophisticated irradiation units as well as new soft- and hardware for calculation and conformal dose delivery. Implementation of three-dimensional stereotactic coordinate systems enable irradiation of small oligometastases with high single doses strictly respecting the limitations of surrounding normal tissue or adjacent risk structures. In most cases hypofractionated concepts with only a few radiation sessions are prescribed. Only recently the term radiosurgery has been introduced, describing the ability to achieve a local ablative impact with a single session.

Stereotactic radiosurgery has initially matured in the treatment of cerebral metastases or recurrent primary neoplasms (e.g. gliomas) or benign tumors (e.g. acoustic neuroma) as well as arteriovenous malformations \[[@B47]\]. Precondition is the fixation of the skull within a stereotactic frame \[[@B30]\] or special synthetic devices to model an individual stiff mask (BrainLab, Munich, Germany) \[[@B48]\].

Stereotactic Body Radiation Therapy (SBRT) {#sec2_4}
------------------------------------------

Significant improvement in local control due to cranial stereotaxis as well as initiation of image-guided radiotherapy (IGRT) and intensity-modulated radiotherapy (IMRT) triggered the transfer of this technique to extracranial indications as SBRT. The simple difference is that targets outside the brain often display significant motion, e.g. due to breathing, exemplified by liver and lung malignancies. Hence, the technical challenges are considerably higher in extracranial locations, and only in the past few years an increasing number of studies on SBRT of liver or lung treatments has demonstrated the increased expertise and reliability of this technique, although current data still varies in outcome measures \[[@B49],[@B50],[@B51]\]. Particularly in SBRT of lung malignancies, there are different techniques used to reduce breathing motion causing geometric instability of the clinical target volume (CTV). Most methods require a physical pressure device. Image guidance for gating and tracking and intensity beam modulation (IMRT) as well as modern calculation algorithms have improved accuracy significantly \[[@B52]\]. The MRI(magnetic resonance imaging)- or CT-based tumor definition (gross tumor volume (GTV)) gains an added safety margin, achieving the planning target volume (PTV) \[[@B52],\]\[[@B53]\]. The safety margin, which depends on the institutionally applied technique, is at least 5 mm in axial and 10 mm in craniocaudal orientation.

SBRT (like cranial SRT) permits precise irradiation. This enables the radiotherapist to lower the dose to adjacent risk structures or 'organs at risk' (OAR) significantly compared to conventional 3D-conformal radiotherapy, thus permitting ablative doses to the tumor. In liver neoplasms of different origins, 1-year local control rates between 71 and 95% have been reported \[[@B42]\]. In inoperable stage 1 non-small cell lung cancers of up to 5 cm, a local control rate of 98% after 3 years was achieved in a multicenter study \[[@B54]\]. However, in contrast to irradiating inside out such as by brachytherapy (BT), the external application mode of SBRT leads to an exposure of large volumes of neighboring tissues to be exposed to considerable doses \[[@B55]\].

SBRT offers an effective treatment with a non-invasive approach, avoiding intervention-related complications like bleeding events. However, effective high radiation doses go along with significant exposure of normal surrounding tissue. This causes relatively strong restrictions with respect to size, number of lesions, and location. The balance between applying effective doses und safety concerns is sometimes difficult to find \[[@B51],[@B56]\]. Published data on the safety of abdominal SBRT describes grade 3 and 4 events in a wide range of 0 to 78 and 0 to 25%, respectively, including gastroduodenal ulcerations, hepatic toxicities, nausea/vomiting, esophagitis, and stenosis of the bile duct \[[@B55]\]. Radiation-induced liver disease seems to be less frequent compared to conventional liver radiotherapy \[[@B55]\] (fig. [1](#F1){ref-type="fig"}).

Brachytherapy: High-Dose-Rate Interstitial Brachytherapy {#sec2_5}
--------------------------------------------------------

BT as a highly effective radiotherapy in various tumors has been conducted for more than 100 years in superficially located tumors or tumors accessible through natural orifices of the body as a contact or intracavitary BT. Sources used include palladium-103 (^103^Pd), iodine-131 (^131^I; low-dose-rate = LDR BT), or ^192^Ir (HDR-BT). Besides the point source position, the dose rate determines the required length of the application to reach a prescribed target dose.

HDR-iBT is a radiation technique used in various locations inside the body, where a point source, e.g. ^192^Ir, is guided through interventionally implanted catheters into the tumor \[[@B45],[@B57],[@B58],[@B59],[@B60]\]. The implementation of this technique in parenchymal tumors was driven by the introduction of 3D planning systems based on CT or magnetic resonance tomography volume data sets and the development of CT and MR fluoroscopy from the nineties as well as early years of the 21st century.

It provides advantages compared to percutaneous irradiation by applying higher doses inside the target volume while saving surrounding parenchyma from unnecessary exposure more sufficiently. Positioning of the BT catheters is accomplished either by fluoroscopy CT or by real-time fluoroscopic MRI. The catheter position, the tumor margin, and the anatomic risk structures are verified by contrast-enhanced images sent to the treatment planning unit.

Limitations of SBRT have been demonstrated in previous studies, such as a limited number of reasonably treatable metastases or a safe lesion diameter up to 4-5 cm \[[@B51],[@B56]\]. Beyond that size threshold, local tumor control rates after SBRT tend to decrease significantly \[[@B61],[@B62]\]. In contrast, CT-guided BT seems to deliver more reliable tumor control even in very large lesions. In previous studies, local tumor control in HCC up to 12 cm was 90% at 1 year. In a randomized controlled dose escalation study on colorectal cancer, local control of liver metastases after iBT was \>90% if a minimum threshold dose (with dramatic dose escalation in the CTV) of 20 Gy was applied in tumors up to 15 cm \[[@B43],[@B45]\]. In addition, repetitive BT has proven to not enhance the procedural or post-therapeutic risk \[[@B63]\]. In pulmonary malignancies of different origins and a tumor diameter of up to 11 cm, a 1-year local control rate of 91% was achieved with single doses between 15 and 20 Gy \[[@B44]\]. iBT is commonly performed in a single session even in larger tumor volumes of up to 10 cm in diameter and more, applying minimal doses inside the CTV of 15-25 Gy (however, inside the target, the doses will be extensively higher the closer the position to the point source or catheter is). High single doses exceeding 8-10 Gy/fraction (as it is also the case in SBRT, if applicable) seem to trigger additional radiobiological phenomena beyond direct cell killing, hence probably boosting the treatment effect, e.g. inducing apoptosis to the vascular endothelium \[[@B64],[@B65]\]. This enables the interventional oncologist to treat even large and centrally located liver lesions effectively \[[@B58],[@B66]\]. Triggering breath or body motion is not necessary since the tumor is fixed by the implanted catheters guiding the point source during treatment. Hypofractionated schemes with two or three fractions are sometimes helpful in locations close to the stomach or duodenum, the cutis, or in very large tumors.

One drawback of iBT is its invasiveness compared to SBRT. However, the frequency of adverse events related to the interventional applicator implantation is still low with bleedings requiring treatment (either transfusion or embolization) amounting to 4% in HCC and to 2.5% in colorectal liver metastases \[[@B43],[@B45]\]. In pulmonary interventions, minor and major pneumothoraxes were observed in 12 and 2%, respectively \[[@B44]\]. The probability of radiation-induced liver disease (RILD) development seems to be very low even after the treatment of very large liver tumors in cirrhosis \[[@B43],\]\[[@B45]\]. Gastroduodenal ulcerations occur seldom after exposure of the gastric or duodenal mucosa to more than 14 Gy \[[@B67]\] (fig. [2](#F2){ref-type="fig"}).

Y90 Radioembolization {#sec2_6}
---------------------

RE using Y90 microspheres is a relatively new modality applicable for use even in patients with extensive liver involvement of primary and secondary liver neoplasms. Recent experience indicates the efficacy of RE in patients with a tumor load up to 50% or diffuse location \[[@B32],[@B68],[@B69],[@B70]\]. However, there still is a lack of evidence from randomized controlled trials such as published on systemic chemotherapies or TACE (only HCC) \[[@B25],\]\[[@B71]\]. Therefore, RE is frequently placed at the end of a therapeutic algorithm after the failure of conventional therapies. In this regard, RE is seen as an exceptional salvage treatment usually conducted at just one time-point per patient. The absence of alternative treatment options after an initial RE raises the question whether a repeated RE would be safe and effective. In individual patients the indication for repeated RE may vary between treatment indications for one or both liver lobes. Safety is of considerable interest in patients with a restricted liver function after previous RE, possibly in combination with hepatotoxic chemotherapies or liver cirrhosis. RE comprises the injection of radioactive either Y90-labelled resin microspheres (SIR-Spheres®; Sirtex Medical, Lane Cove, Australia) or Y90-labelled glass spheres (TheraSphere®; BTG, London, UK) into the arterial hepatic circulation. The spheres are designed to accumulate specifically in tumor tissue due to the dual liver blood supply. Anti-tumor efficacy is linked to the beta radiation from Y90 which decays with a physical half-life of 64 h (approximately 2.7 days). Prior to RE, an angiography of the celiac trunk is performed, usually including coil embolization of the gastroduodenal artery and right gastric artery to avoid extrahepatic accumulation of microspheres. After coil embolization, injection of Tc99m-MAA (Technetium-99m bound to macro-aggregated albumin) into the hepatic artery is performed to rule out a relevant shunt volume to the lung or extra-hepatic accumulation (e.g. stomach). Therapy with active spheres is performed as total liver irradiation or, to better preserve liver function, sequentially in two separate procedures for the right and left liver lobes at an interval of 4-6 weeks, assuming that both liver lobes are involved.

There is evidence for the effectiveness of RE in cancer patients with more or less extensive liver involvement. For salvage RE in colorectal liver metastases, OS of 14.5 months \[[@B72]\], 10.5 months \[[@B73]\], and 10 months \[[@B74]\] have been reported. Seidensticker et al. \[[@B75]\] showed the superiority of RE over best supportive care for salvage colorectal liver metastases in a matched-pair analysis.

These results are noteworthy, especially when compared to systemic treatment in the second- to third-line setting. In a second-line situation, a FOLFIRI regimen in 213 patients resulted in a PFS of 5.1 months \[[@B76]\]. In a third-line situation, bevacizumab plus FOLFIRI or FOLFOX resulted in a PFS and OS of 5.3 and 9.5 months, respectively \[[@B77]\]. Adverse events in the aforementioned trial included grade 3-4 neutropenia in approximately 43%, fatigue in 22%, neuropathy in 22%, and mucositis in 22% of all patients.

In HCC, present data suggests that RE is best placed after TACE failure in the intermediate stage (EASL/EORTC guidelines) or in patients with diffuse (\>4 tumors) or large tumors (\>5 cm) \[[@B32],[@B78]\]. Salem et al. \[[@B79]\] reported an OS of 17.2 and 7.7 months for 291 patients with HCC, depending on the Child-Pugh stage (A or B). The most apparent difference to TACE, however, is the fact that TACE has evolved as a repetitive procedure which is not the case for RE. Despite the fact that the effect of RE vanishes over time, RE has been adopted as a single therapeutic approach, although there is some evidence that repetitive RE is safe based on patient selection and when certain preconditions such as preserved liver function are met \[[@B70],[@B80]\]. In addition to HCC, the next most common indications for RE are colorectal cancer, breast cancer, and neuroendocrine liver metastases \[[@B81]\].

Despite combination schemes, RE offers a rather short treatment time in contrast to systemic treatments, which continue over weeks. Most common side effects include grade 1-2 fatigue in up to 40% during the first 2 weeks after treatment or mild nausea during the first few days. Severe complications are rare and include gastric ulcer (\<3%) by accidental implantation of spheres in the gastric mucosa, or RILD due to overexposure of functional liver parenchyma. The incidence varies depending on patient selection, preventive measures, and dosimetry (normally \<5%; up to 20% in high-risk patients) \[[@B69],\]\[[@B82],[@B83],[@B84]\] (fig. [3](#F3){ref-type="fig"}).

Discussion {#sec1_3}
==========

Various local treatment approaches claim a curative potential in limited metastasized stages of various tumors, ultimately basing upon the concept of oligometastatic disease \[[@B10],[@B11],[@B12]\]. The strongest evidence today exists for the resection of liver metastases \[[@B6],[@B7],[@B8],[@B9]\]. However, non-surgical methods such as thermal ablation and radiotherapeutic approaches have been introduced recently, essentially targeting patients not eligible for surgery. This evolution will potentially have a major impact on patient management and outcome -- one should bear in mind that most patients with metastatic gastrointestinal tumors present with unresectable disease. The proof of equality compared to surgery should therefore not be the mainstay of clinical interest or prospective study protocols, although it has already been proven for selected indications (e.g. RFA in HCC). In the majority of patients, resection or ablation are not competitive but rather complementary. Given the local control rates of image-guided ablation as compared to R1 resection rates, e.g. in liver metastases of colorectal cancer, most likely a mentality allocating the more curative intention to surgery and the more palliative intention to local ablation will help guiding patient selection. The difficulty of the concept of oligometastatic disease, however, is the discrimination between patients with oligometastatic 'phenotype' but undiscovered polymetastatic nature and those who are 'truly' oligometastatic with a rather benign tumor biology. Tumor markers, gene expression profiles, or mutational status are yet to be identified to help in aiding therapeutic decisions for local treatment of metastasized patients \[[@B85]\].

There is increasing evidence that radiotherapeutic techniques in parenchymatous and glandular organs, lymph nodes, and soft tissues are effective, tumoricidal treatments beyond the technical capabilities of thermal ablation such as RFA \[[@B11],[@B61],[@B64],[@B75],[@B86],[@B87],[@B88],[@B89],[@B90]\]. To some extent, as well as differentially, SBRT, iBT, und RE overcome the limitations of RFA as the most commonly used local ablative technique worldwide with respect to size, location, and number of lesions treated \[[@B40],[@B41]\]. As a consequence, the spectrum of non-surgical ablative methods is expanded and the indications are widened. SBRT as well as iBT offer highly precise conformal radiation and therefore enable the application of radiosurgical doses to a wide range of neoplastic appearances. Concurrently, both methods allow a reduced exposition of the surrounding and adjacent tissue or structures (e.g. intestinal mucosa), consequentially avoiding an overexposure of adjacent normal tissue and risk structures. The hypofractionation with doses above 8-10 Gy (high single doses) evoke radiobiological effects beyond mitotic cell death like apoptosis to the vascular endothelium, therefore facilitating radioablation \[[@B64],[@B65]\]. An advantage of high-dose single-fraction SBRT is its non-invasiveness without potential intervention-related hazards such as bleeding events, occurring still seldom in interstitial BT. In contrast, iBT overcomes limitations of SBRT with respect to size and location \[[@B43],[@B45],[@B58],[@B66]\]. Therefore, we suggest that the stratification of patients to receive SBRT or iBT might follow the rule that in single lesions up to 5 cm SBRT should be applied, whereas in larger or multiple lesions iBT may facilitate a more reliable tumor control. In more advanced cases, RE will probably be the method of choice \[[@B75]\].

Stratification for either local radiotherapeutic treatments or RE will most likely be based on the total number of lesions, enabling treatment in a reasonable period of time \[[@B91]\] (fig. [4](#F4){ref-type="fig"}).

At present, Y90-RE is the only radioablative method for diffuse liver metastases. Today it is usually prescribed in salvage patients. This restriction to salvage may be overcome once SIRFLOX trial results are published. In this particular trial, RE is combined with FOLFOX and Avastin in the firstline treatment of multifocal, irresectable colorectal liver metastases. Patient recruitment has been completed, and first results are expected by the end of 2014. The SIR-step trial is recruiting and compares Y90-RE plus systemic maintenance therapy versus maintenance therapy alone after successful induction systemic therapy. In HCC, the only current prospective randomized study design considering repetitive treatments in intermediate and advanced stage HCC is SORAMIC, which is considered to continue recruitment until mid-2015/2016. Preliminary safety data is already available \[[@B82]\].

Conclusion {#sec1_4}
==========

Radiation therapy offers considerable contributions to the multimodal management of solid tumors not only in the standard palliative setting but also in a curative intention by applying radioablative approaches such as SBRT or CT-guided BT. In oncological terms, the question to be answered today is not whether a local tumor ablation can technically be managed, but which patient is benefitting from such a therapy and how should the overall treatment concept including systemic approaches look like. Better understanding of the oligometastatic concept and identification of according biomarkers would dramatically benefit patients with metastases of gastrointestinal or other tumors. Ultimately, best patient care can be offered in institutions supplying a large tool box including open and laparoscopic surgery, image-guided ablation by thermal or radiation methods, locoregional approaches such as RE or TACE, as well as systemic chemotherapy options -- and most importantly, experience on the best sequence and combination of such methods with systemic treatments.
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![Isodose lines: right hilar metastases of colorectal cancer, high dose coverage of tumor achieves an acceptable exposure to surrounding tissue (lung, heart).](vim-0030-0245-g01){#F1}

![**a** Two hypointensed metastases in MRI with primovist; **b** final scan with catheters (white lines) within the tumor; **c** same scan with tumor-surrounding isodoses, showing sufficient coverage.](vim-0030-0245-g02){#F2}

![Angiography of the left hepatic artery documenting the intra-arterial RE with Y90 microspheres **(left)**; postprocedural 'Bremsstrahlen' szintigraphy conforming the deposit in the left liver lobe **(right)**.](vim-0030-0245-g03){#F3}

![**a** HCC, left lobe segment III, iBT; sufficient isodose covering CTV, low whole liver exposition due to steep dose drop-off of the ^192^Ir source; **b** same case; virtual SBRT calculation, with dose-volume histogram showing different exposure of the whole liver.](vim-0030-0245-g04){#F4}
